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A B S T R A C T
The mammalian hearts have the least regenerative capabilities among tissues and organs. As such, heart re-
generation has been and continues to be the ultimate goal in the treatment against acquired and congenital heart
diseases. Uncovering such a long-awaited therapy is still extremely challenging in the current settings. On the
other hand, this desperate need for effective heart regeneration has developed various forms of modern bio-
technologies in recent years. These involve the transplantation of pluripotent stem cell-derived cardiac pro-
genitors or cardiomyocytes generated in vitro and novel biochemical molecules along with tissue engineering
platforms. Such newly generated technologies and approaches have been shown to effectively proliferate car-
diomyocytes and promote heart repair in the diseased settings, albeit mainly preclinically. These novel tools and
medicines give somehow credence to breaking down the barriers associated with re-building heart muscle.
However, in order to maximize efficacy and achieve better clinical outcomes through these cell-based and/or
cell-free therapies, it is crucial to understand more deeply the developmental cellular hierarchies/paths and
molecular mechanisms in normal or pathological cardiogenesis. Indeed, the morphogenetic process of mam-
malian cardiac development is highly complex and spatiotemporally regulated by various types of cardiac
progenitors and their paracrine mediators. Here we discuss the most recent knowledge and findings in cardiac
progenitor cell biology and the major cardiogenic paracrine mediators in the settings of cardiogenesis, con-
genital heart disease, and heart regeneration.
1. Introduction
Since the human heart has a significantly limited ability to repair
itself following injury, heart regeneration has long been sought after yet
remains extremely hard to accomplish and thus in high demand for
cardiovascular researchers and clinical cardiologists. Currently, stan-
dard of care treatment options offer little hope for a wide variety of
severe forms of heart diseases including ischemic cardiomyopathy fol-
lowing myocardial infarction (MI) in adults and congenital cardiac
birth defects in children. Thus, there is an urgent need to develop novel
therapeutic approaches to better treat severe heart disease and improve
the quality of life for the affected patients. In this regard, recent ad-
vances in stem cell biology and biotechnologies have helped us to gain a
deeper understanding of the cellular and molecular mechanisms in
heart formation and development. In addition, these new findings and
the updated knowledge in this field hold great promise for cardiac re-
generative medicine [1,2].
The human heart is a complex organ system and composed of highly
diverse cell types, which are originally derived from mesodermal pre-
cursors and multipotent cardiac progenitors at early embryogenesis
[3–6]. From the molecular viewpoint, multiple signaling pathways, as
well as transcription factors and other mediators sequentially play es-
sential roles during cardiogenesis [7,8]. Identifying various cardiac
progenitor subpopulations and paracrine mediators is critically im-
portant to understand heart development and also the pathogenesis of
congenital heart disease (CHD) in humans. New knowledge and dis-
coveries in these areas may lead to novel strategies for heart re-
generation and perhaps new treatment such as cell-based or cell-free
regenerative therapy [1,2,9,10]. In this review, we describe the most
recent notions in cardiac progenitor cell biology and the cardiogenic
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paracrine mediators in the settings of cardiogenesis and CHD, and
thereafter discuss novel strategies for therapeutic heart regeneration.
2. Cardiac progenitors in cardiogenesis and heart regeneration
2.1. Embryonic cardiac progenitors
The vertebrate heart forms a complex three-dimensional structure in
the early embryonic stages by a wide variety of cell types: cardio-
myocytes (CMs), conductive cells (CCs), vascular smooth muscle cells
(SMCs), endothelial cells (ECs), and cardiac fibroblasts. These cell types
are derived from multipotent cardiac progenitors, which are self-re-
newing clones defined by their spatiotemporal presence and potential
to differentiate into these specific lineages. Various types of meso-
dermal precursors and the earliest cardiac progenitors are present be-
fore commitment to either of the first or second heart field (FHF or
SHF). Brachyury (Bry), a transcription factor and a member of the T-box
family of genes has been shown to define the mesoderm during gas-
trulation and to be critical for mesoderm formation, thereby re-
presenting a mesodermal precursor marker [11–14]. Bry+cells have the
capacity to differentiate into Isl1 and Tbx5 expressing cells in humans,
and further they have been shown to differentiate in vitro into the major
cardiac cell populations: CMs, and vascular SMCs and ECs [12,15,16].
Another T-box transcription factor Eomes is also a critical intrinsic
factor that initiates mesoderm differentiation and patterning of the
primitive streak [11]. Eomes induces expression of mesoderm posterior
1 (Mesp1) as a downstream target [17,18]. Mesp1 is an essential reg-
ulator of cardiac mesoderm commitment in mammals and thus, marks
the earliest cardiac progenitors within the primitive streak from em-
bryonic day 6.25 (E6.25) to E7.25 in mice [19,20]. Mesp1+cells can be
identified preceding the separation into the FHF and SHF, where it has
been shown that early FHF and SHF progenitors express a transcription
factor NK2 homeobox 5 (Nkx2-5) at E7.5 in mice [19,21,22]. Another
early cardiac progenitor population in humans has been defined by the
expression of stage-specific embryonic antigen-1 (SSEA-1). SSEA-
1+cells have been shown to express markers of both the FHF and SHF
and differentiate into CMs, SMCs and ECs [23]. They have even been
used as a sorting marker for cardiac progenitors in a heart failure
clinical trial [24]. Similar to SSEA-1, vascular endothelial growth factor
type 2 receptor Flk-1, also known as kinase insert domain protein re-
ceptor (KDR), and platelet derived growth factor receptor alpha
(PDGFR-α) are shown to be one of the earliest cardiac progenitor cell
surface markers in mice and humans, as the Flk-1 (KDR)+or PDGFR-
α+cells were demonstrated to give rise to CMs, SMCs and ECs in vi-
troand in vivo [12,15,25,26].
The FHF derives its name from harboring the first differentiated
myocardial cells which specifically express the ion channel hyperpo-
larization-activated cyclic nucleotide-gated channel 4 (HCN4) [27]. The
majority of CMs in the left ventricle and a small population of CMs in
the right ventricle are derived from the HCN4+progenitors, together
with parts of the atria, and CCs from both the sinoatrial and atrio-
ventricular nodes, and the ventricular conduction system [27,28]. The
transcription factor Islet1 (Isl1) marks the SHF progenitors, which mi-
grate from the pharyngeal mesoderm to the posterior side of the heart
tube where morphological extension and looping occur [4,29–31].
Through contributions to several cardiac lineages, the SHF forms the
majority of the right ventricle and parts of the atria and the outflow
tract [4,31,32]. Besides the major contributions of the FHF to the left
ventricle and the SHF to the right ventricle, field-specific progenitor cell
populations have also been shown to support a minor contribution to
the opposing ventricles as well [3,7].
The proepicardial organ (PEO) is a mesodermal precursor-derived
transient structure which eventually forms the epicardium [33]. A
murine linage tracing study suggested that Nkx2.5+ and/or Isl1+ car-
diac progenitors contribute to PEO formation, and that Nkx2-5, but not
Isl1, is functionally required for PEO development [34]. The PEO
comprises two subpopulations, namely Wilms tumor-1 (Wt1) and T-box
18 (Tbx18)-positive cells, which mainly contribute to the SMC and
cardiac fibroblast populations, and the semaphorin 3D (Sema3d) and
scleraxis (Scx)-positive cells which additionally contribute to the EC
population [35–37]. After migration of the PEO derivatives over the
entire surface of the heart and formation of the epicardium, a sub-
epicardial mesenchyme is formed by epithelial to mesenchymal trans-
formation of epicardial cells overlying the atrioventricular groove
[38,39]. Of note, Wt1+ epicardial progenitors contribute to not only
SMC and cardiac fibroblast formation but also cardiac endothelial cell
formation within the myocardial ventricular layer of the developing
heart in mice and humans [40,41]. It is a point of current debate if these
epicardium-derived cells can contribute to the CM lineage [35–37,42].
A great number of these murine studies mentioned above and below
employ fate mapping strategies with Cre/Lox technologies. It is im-
portant to note several limitations with this technology including: 1)
The promoter driving Cre expression may be expressed at low levels in
some untargeted cell types and induce accidental recombination (e.g.,
Wt1 is also expressed in some myocardial cells and this might possibly
lead to misinterpretations on epicardium giving rise to myocardium); 2)
If a non-inducible Cre is used, no conclusion on the cell fate can be
ascertained as a positive signal might represent Cre expression at the
time of analysis; and 3) A good control on leakiness is needed (e.g.,
CreERT2 may be active in the absence of tamoxifen).
The majority of the developed heart is composed of cells derived
from the FHF and SHF progenitors, yet some components consist of cells
derived from the cardiac neural crest cells (CNCCs). CNCCs originate
from the dorsal neural tube with expression of Wnt1, Pax3 and Sox10
and migrate through the posterior pharyngeal arches to the arterial pole
of the heart tube at around E9.5 in mice [43–46]. CNCCs and their
derivatives give rise to SMCs of the pharyngeal arch arteries and cardiac
cells of the outflow tract. They are involved in the formation of the
cardiac valves, the parasympathetic nerve system and outflow tract
patterning and septation [44,47–49].
2.2. Newly identified cardiac progenitors in cardiogenesis
Recent advances of biotechnologies involving multi-color lineage
tracing, single-cell RNA and DNA sequencing, CRISPR-CAS genome
editing, etc., have identified previously unknown cardiac progenitor
populations that would play certain roles in cardiogenesis. For example,
an elegant study by Cui et al. demonstrated how single cell tran-
scriptomics provides new techniques to identify and map out human
developmental cardiogenesis [50]. Taken together, these new findings
and advances in technologies enable us to understand the cellular and
molecular mechanisms in cardiogenesis in a spatiotemporal manner
more deeply. The novel cardiac progenitor populations may also be
relevant for pathogenesis of CHD and/or serve as therapeutic tools for
heart regeneration.
Lee et al. have recently reported a cardiac progenitor population
identified by the G protein-coupled cell surface receptor latrophilin-2
(Lphn2) [51]. Deletion of Lphn2 in murine embryonic stem cells (ESCs)
significantly decreased their ability to express the cardiac lineage-re-
lated genes such as Gata4, Nkx2-5, Tbx5 and Isl1 during cardiac dif-
ferentiation. The decline in cardiomyogenic gene expression subse-
quently resulted in a significantly decreased number of cardiac troponin
T (Tnnt2)-positive cells that emerged after 10 days of differentiation. In
vivo these impairments were validated and resulted in defective for-
mation of the right ventricle, atrium and outflow tract, eventually
causing a small and single ventricle ultimately leading to embryonic
lethality in Lphn2−/− mice [51]. Lphn2−/− embryos also showed
markedly reduced expression of Gata4,Nkx2.5,Tbx5, Isl1 and Tnnt2
genes, although the detailed mechanisms to clarify a role and function
of Lphn2 on induction of these cardiogenic genes were unknown.
The majority of cardiac progenitors have been identified in mice,
though gene expression profiles differ significantly between human and
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rodent species [50]. Utilizing population and single-cell RNA sequen-
cing in human ESC and embryonic/fetal heart derived cardiac cells, our
group has recently described a human specific cardiac progenitor po-
pulation [52]. This population is marked by the expression of the leu-
cine-rich repeat-containing G-protein coupled receptor 5 (LGR5), in-
volved in the Wnt signaling pathway. LGR5 has previously been shown
to mark stem cells in various other organs, including intestin, colon,
kidney, hair and follicle [53,54]. Intriguingly, deletion of LGR5in
human ESCs using the CRISPR-Cas9 technology confirmed less efficient
cardiomyocyte induction or differentiation through impaired expansion
of Isl1+Tnnt2+ intermediates [52]. In vivo, LGR5+cells were found in
the proximal outflow tract (cono-ventricular) region in the early stage,
i.e., at 4–5 weeks of human fetal development. Importantly,
LGR5+cono-ventricular progenitors appear to be specific in humans as
they are not found in murine embryonic hearts, suggesting that the
population would be associated with human-specific mechanisms of
cardiogenesis and also the pathology underlying CHD where mechan-
isms of defective development are largely unknown.
Recently, another zinc-finger transcription factor, Spalt-like gene 1
(Sall1)has been reported to mark undifferentiated heart precursors in
both heart fields and thereby represent a unique subset of the early
cardiac progenitors giving rise to both left and right ventricles in mice
[55]. Sall genes are the vertebrate homologs of the Drosophila homeotic
gene, spalt, and have been shown to play pertinent roles in the em-
bryonic development of the limb [56,57]. The team showed Sall1 was
transiently expressed in pre-cardiac mesoderm contributing to devel-
opment of the FHF and SHF and its expression was maintained in the
SHF but not in FHF or differentiated cardiac cells [55]. In vitro, high
levels of Sall1 protein at mesodermal stages enhanced cardiomyogen-
esis, whereas its continued expression suppressed cardiac differentia-
tion, indicating the role of Sall1as a regulator of cardiac progenitor
maintenance and cardiac differentiation.
Other interesting and novel cardiac progenitor populations include
the Hopx+, Foxa2+ and Gfra2+cells, which are described elsewhere
[9]. In brief, Hopx (homeodomain-only protein homeobox) expression
initiates shortly after the emergence of both heart fields (Nkx2-5+), and
Hopx+ cells are fully committed to CMs distributed across all the adult
heart chambers and essential for cardiac development in mice [58].
Interestingly, a recent single-cell RNA-seq study of the in vitro cardiac
differentiation has also shown that Hopxis a key regulator of CM hy-
pertrophy and maturation in vitro [59]. Bardot et al. have recently re-
ported that Foxa2 (forkhead box protein A2)+ cells are specified during
gastrulation when they transiently express Foxa2 and that those cells
represent a cardiac progenitor population with ventricular specifica-
tion, giving rise primarily to CMs of the ventricles and only a few atrial
cells of the differentiated heart in mice [60]. On the other hand, Ishida
et al. have shown that Gfra2 (Glial Cell Line Derived Neurotrophic
Factor Family Receptor Alpha 2) identifies a specific cardiac progenitor
population functioning for cardiac compaction [61].
2.3. Adult cardiac progenitors and their potential for heart regeneration
The human heart possesses the ability to renew CMs, albeit very
limited. Bergman et al. elegantly showed, using 14C labelling, that 0.5
%–1 % of CMs renew yearly, resulting in a total of 40 % of CMs being
replaced after a lifespan [62]. Although the origin of the newly gen-
erated CMs is of current debate, these findings suggest the presence of
either a dividing population of preexisting CMs, differentiation of local
resident cardiac progenitors, or both in the adult heart [63–66]. A more
recent study investigated turnover of several cell-types in the heart
more thoroughly, confirming CM exchange is highest in the peri-natal
period, while interestingly, endothelial cells and mesenchymal cells
continue to turn-over at much higher rates throughout life [67]. Several
populations of endogenous cardiac progenitor cells in the adult mam-
malian hearts have been identified; however, it is likely that these
“adult” cardiac progenitors reported to date contribute only rarely to
direct cellular generation of new CMs in the adult setting, as described
below [68].
Cells expressing the hematopoietic stem cell marker tyrosine kinase
receptor c-kit have been isolated from the adult human heart and used
as the adult cardiac progenitor marker [69,70]. The cardiac c-kit+cells
were reported to result in improved cardiac function when clinically
injected in patients with ischemic cardiomyopathy [71], although that
clinical trial (SCIPIO) was highly controversial and recently retracted
[72]. In addition, the mechanisms underlying these debated effects are
unknown as recent reporter and lineage tracing studies in mice have
shown that c-kit+ cells do not, or insignificantly, contribute to new CM
formation during normal ageing or following injury such as MI in vivo
[73–75]. Instead, c-kit predominantly labels a cardiac endothelial cell
population in developing and adult hearts with or without injury [73],
which is consistent with the recent study reporting that the majority
(≈90 %) of the resident c-kit+cells in the rodent heart are blood/en-
dothelial lineage-committed cells (CD45+CD31+) [76]. Collectively,
their potential cardioprotective effects might be mainly due to secreted
factors acting in a paracrine fashion rather than direct cellular con-
tributions to newly generated heart muscle [77–79].
Besides their essential roles during cardiac development, un-
differentiated Isl1+ cells are present in very low numbers in the adult
heart in mammals, mainly located in the atria [29,80]. However, their
potential role for heart regeneration is questioned as they do not pro-
liferate postnatally, even when CMs are still dividing [80].
Flk-1 (KDR)+ cardiovascular progenitors were shown to contribute
to the embryonic formation of the CM, EC and vascular SMC lineages
[12,15], while their presence and/or potential roles in the adult hearts
are not well determined. A recent study has reported that in adult rats,
Flk-1 (KDR)+ cells were detected in the pericardial adipose tissue and
capable of giving rise to both myogenic and angiogenic precursors in
vitro. It was further shown that after purification and transplantation of
these Flk-1 (KDR)+ cells in vivo, they could reconstitute the damaged
heart in rats by the neoformation of microvasculature and of CMs, al-
though these effects were mainly derived from the paracrine effects but
not from the direct cellular contributions of the injected cells [81].
To isolate more putative and suitable cardiac progenitors in the
adult heart, several groups used additional markers from mouse he-
matopoiesis, such as Stem cell antigen-1 (Sca-1) that is a mouse specific
progenitor cell marker [82]. Other teams have used the ability to grow
putative cardiac progenitors in three-dimensional clusters called car-
diospheres [83]. Although the initial reports indicated the cardiomyo-
genic potential of the Sca-1+cells [84–86], recent lineage tracing stu-
dies in mice have demonstrated that Sca-1+cells exhibit endothelial but
not myogenic contribution to the murine heart [87,88]. Cardiosphere-
derived cell populations are heterogenous and their composition de-
pends on the age of the subject they are derived from, with cells derived
from neonatal hearts harboring the strongest regenerative capacity
[83,89,90]. Injection of autologous cardiosphere-derived cells has been
shown safe and beneficial in many preclinical models and the CADU-
CEUS clinical trial [83,91,92]. In the CADUCEUS trial, 17 patients with
left ventricular dysfunction after MI received autologous cardiosphere-
derived cells through intracoronary infusion in the infarct related ar-
tery. Cells were obtained from endomyocardial biopsies 2–4 weeks after
infarction and administered within an average time of 36 days after
biopsy. Significant decreases in scar size and increases in viability and
regional function (but not global function) were observed after 1 year
[91,92]. Since the engraftment rates are low, paracrine effects, and
more recently exosomes and micro-RNAs have been identified as the
putative cardioprotective mechanisms of cardiosphere-derived cell
therapy [79,93–96].
Chong et al. isolated a cell population, termed cardiac colony
forming units–fibroblasts (cCFU-F), resembling mesenchymal stem cells
using FACS enrichment for Sca1+PDGFRα+CD31− cells from adult
murine hearts [97,98]. These cells had a proepicardial origin and could
give rise to a wide range of cell types, mainly cardiac fibroblast and
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stromal cells, but with the right chemical cues they could also generate
low amounts of CMs [98]. In a human setting, PDGFRα+ cells were
found in the interstitial cells of the epicardium, myocardium, and en-
docardium, as well as the coronary smooth muscle cells in the adult
heart [25]. Only rare ECs and CMs in the heart expressed PDGFRα,
although their presence increased in diseased hearts. In vitro, these
PDGFRα+ cells did not differentiate into CMs using the 5-azacytidine
protocol, but large numbers of SMCs and ECs could be obtained [25]. Of
further interest was a recent finding that observed a novel resident
cardiac mesenchymal stem cell (MSC) niche identified as
CD44−CD44+DDR2+ which became pro-proliferative following MI in
rats [99]. Of note, the team demonstrated a promoting role by ery-
thropoietin in the stimulation of cardiac mesenchymal proliferation,
which showed the newly identified cardiac MSCs exerted cardiomyo-
genic and angiogenic properties. Furthermore this newly identified
MSC population also accelerated a healing process through trans-
forming growth factor β (TGF-β) and wingless-int (Wnt) signaling
pathways [99]. Very recently, Valente et al. identified another popu-
lation of immature cardiomyocytes marked by cell surface markers,
heat stable antigen (HSA) and CD24 in both embryonic and adult hearts
in mice [100]. The team has found that the HSA/CD24+ CM subset
actively proliferated up to 1 week of age and engrafted cardiac tissue
upon transplantation. Interestingly, in the adult heart following MI
injury, a 3 fold increase in HSA/CD24+ mononucleated CMs with
modest Ki67 expression was observed around the areas of MI [100].
Other subpopulations of the epicardium, such as Wt1 and Tbx18
expressing cells have been of interest for their ability to differentiate
into CMs following injury [36,37]. Wt1+ cells in mice were successfully
mobilized and differentiated into CMs as well as ECs with the use of a
single injection of modified mRNA encoding vascular endothelial
growth factor A [101]. Finally, side population (SP) cells from neonatal
rat hearts have been reported to home to the heart after injury and
differentiate into CMs, SMCs and ECs [102]. The SP cells are a het-
erogenous population of cells representing 0.02–2 % in adult murine
hearts [103,104]. As this population is defined by their ability to efflux
the DNA-binding dye Hoechst 33342 from their nucleus, lineage tracing
experiments that require a specific marker cannot be performed, which
makes it difficult to interpret the results of the studies employing the SP
cells, mechanistically [103].
3. Cardiogenic paracrine mediators in cardiogenesis and
congenital heart disease
Multiple signaling pathways play critical roles during cardiogenesis
in a sequential and coordinated fashion. The major signaling pathways
involved in cardiac development include the TGF-β superfamily, Wnt,
fibroblast growth factors (FGFs), Hedgehog, Notch and Retinoic acid
pathways [1]. These signaling pathways, in concert with transcription
factors and epigenetic regulators, control cardiac progenitors’ specifi-
cation, proliferation and differentiation into diverse cardiac cell
lineages and contribute to building the entire heart. Below, we offer
detailed descriptions of these major signaling pathways and their im-
portance in normal cardiac development (Section 3.1) and in the pa-
thogenesis of CHD (Section 3.2). In addition, in Section 3.3, we focus on
more details of each paracrine mediator and describe how these factors
exert cardiomyogenic and/or vasculogenic effects and how they have
been applied in a regenerative context.
3.1. Cardiogenic signaling pathways in cardiogenesis
3.1.1. TGF-β superfamily signaling pathway
The TGF-β superfamily members contain more than 30 structurally
related polypeptide growth factors including TGF-βs, bone morphoge-
netic proteins (BMPs), activin and nodal [105]. TGF-β signals via their
protein kinase receptors and downstream mediators, Smads, which
regulate a plethora of biological processes. BMPs are indispensable for
gastrulation and primitive mesoderm formation in mammals. Previous
studies showed that deletion of Bmp4 or a BMP type I receptor (Bmpr1a)
in the germline system caused embryonic death before E9.5 in mice
[106,107]. Further, conditional deletion of Bmp4 or Bmpr1a under the
mesodermal and cardiomyogenic Cre drivers such as Mesp1-Cre, Nkx2-
5-Cre, or Tnnt2-Cre mouse lines results in abnormal cardiac morpho-
genesis, respectively, highlighting the essential roles of BMPs for car-
diac specification and development [108–111]. Interestingly, condi-
tional deletion of Bmpr1a using the Isl1-Cre mice caused right ventricle
and outflow tract hypoplasia with an increased number of un-
differentiated Isl1+ cells, indicating that the activation of BMP sig-
naling is important for the second heart field (SHF) progenitors’ dif-
ferentiation and myocardium maturation [108,112]. Recently, the
single-cell RNA-seq analysis using wild type and Mesp1-knockout (KO)
murine embryos has revealed that among Mesp1+ mesodermal pre-
cursors, Bmp4 could distinctly mark the cardiomyocyte (CM)-com-
mitted population at E7.25 without co-localized expression of an en-
dothelial cell marker Sox7 [113,114].
Activin and nodal are also important regulators of gastrulation,
primitive streak and mesoderm/endoderm formation, left-right asym-
metry of the body axis, and positional patterning in early embryos and
later for cardiomyogenesis [115,116]. Interestingly, a recent study has
revealed that the genes encoding the activin A subunit Inhbaa was
critical for organization of atrioventricular canal (AVC)-localized ex-
tracellular matrix (ECM), facilitating migration of epicardial progeni-
tors onto the developing heart tube in zebrafish [117].
Smad4 is a core transcription factor of the TGF-β signaling pathway.
Loss of the Smad4 gene has no effects on the self-renewal of human
ESCs (hESCs), but causes a subsequent complete loss of CM induction
during the in vitro hESC cardiogenesis, suggesting an essential role of
Smad4 for the formation of cardiac mesoderm [118].
3.1.2. Wnt signaling pathway
The Wnt signaling pathway participates in multiple developmental
events during embryogenesis. The Wnt family has 19 different Wnt
proteins and 10 types of Frizzled receptors [119]. These Wnt and
Frizzled receptors can be divided into two major classes based on their
primary functions, the canonical and non-canonical Wnt pathways
[120]. The function of the canonical Wnt pathway is exerted through
the active β-catenin/TCF transcriptional complex in the nucleus. The
canonical Wnt ligands include Wnt1, Wnt2a, Wnt3a, and Wnt8
[121,122], while the non-canonical Wnt ligands such as Wnt5a, Wnt4
and Wnt11 act through the Wnt/calcium and Wnt/JNK pathways
[123]. Before gastrulation, the canonical Wnt signals are involved in
the formations of primitive streak, mesoderm and endoderm [124]. But,
after gastrulation, a secreted Frizzled-related protein (sFRP) and Dick-
kopf1 (Dkk1) secreted from the adjacent endoderm inhibit these sig-
nals. This spatiotemporal inhibition of the canonical Wnt signaling is
essential for further cardiac specification in the mesoderm [125]. These
biphasic effects of the canonical Wnt signals are also recapitulated in
cultured mouse and human pluripotent stem cells (PSCs) in vitro. The
active Wnt/β-catenin signals promote mesoderm and endoderm for-
mation in the early phase of the PSC differentiation yet inhibit cardiac
myogenesis after the mesoderm has been once established [126–129].
The canonical Wnt signaling also plays an important role at later stages
of embryonic cardiogenesis, which involves both the proliferation and
maintenance of the SHF progenitors and the prevention of their dif-
ferentiation [130]. Conditional deletion of the β-catenin gene using the
Mef2c-Cre mouse line led to right ventricular and outflow tract hypo-
plasia with a dramatic reduction in the number of the Isl1+ SHF pro-
genitors, while enhanced β-catenin expression in the Isl1+ SHF pro-
genitors led to right ventricular enlargement and hyperplasia with an
increase in the number of Isl1+ cells [131,132]. Interestingly, recent
studies have revealed that Alpha Protein Kinase 2 (ALPK2) is the pro-
mising candidate for negative regulators of the Wnt/β-catenin signaling
pathway and promotes cardiac differentiation and maturation in hESCs
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and zebrafish analyzed by antisense knockdown and CRISPR/Cas9
mutagenesis [133]. Furthermore the canonical Wnt signaling specifi-
cally regulates specification of the SHF, but not the FHF, since the ad-
dition of Wnt3A in pre-cardiac organoid models resulted in a further
increase in the SHF markers’ expression and a reduction in the FHF
markers’ expression [134].
The non-canonical Wnt signaling is also required for cardiac speci-
fication and differentiation. Wnt5a- or Wnt11-null mice showed im-
paired pharyngeal artery patterning and outflow tract defects
[135,136]. Inversely, overexpression of Wnt11 promoted cardiac spe-
cification and differentiation of the cardiac progenitors derived from
murine ESCs in vitro [128].
3.1.3. FGFs signaling pathway
The FGF signaling pathway includes more than 20 ligands and 4
transmembrane receptor tyrosine kinases [137,138]. Four members of
them (FGF11–14) are intracellular proteins that do not interact with
FGF receptors (FGFRs) [139–141]. The FGFR-like 1 (FGFRL1) protein
lacks an intracellular tyrosine kinase domain [142]. Most members of
the FGF family play important roles as paracrine or endocrine signals in
heart development and disease [143]. During differentiation of human
PSC (hPSCs), FGF2 specifically promotes mesoderm-committed pre-
cursors’ formation [144]. Fgf8 is expressed in the early posterior dorsal
mesoderm, and the Fgf8-KO mice died at the gastrulation stage due to
the lack of embryonic mesoderm-derived structures [145]. Conditional
deletion of the Fgf8 gene using the Tbx1-Cre mice led to impaired
outflow tract morphologies, suggesting that mesodermal Fgf8 expres-
sion is essential for formation of the SHF-derived structures [146]. In
fact, Fgf8 regulates the expression of the SHF marker genes Isl1 and
Mef2c in mice [147]. Fgf9 and its relatives Fgf16 and Fgf20 are ex-
pressed in both murine endocardium and epicardium at mid-gestation
and contribute to myocardial proliferation and maturation [148]. In-
deed, the proliferative capability of Fgf9-mutant CMs was significantly
diminished [148]. FGF10 promotes CM differentiation and proliferation
in vitro and in vivo, and over expression of the Fgf10 gene in transgenic
mice induced the cell-cycle re-entry of adult CMs [146,147]. The em-
bryonic hearts of the Fgf10-KO mice showed impaired right ventricular
morphology [149]. Similarly, conditional deletion of the FGFR type 1
(Fgfr1) and type 2 (Fgfr2) genes using the ventricle-specific driver
Mlc2v-Cre mice caused severe ventricular defects [148].
3.1.4. Hedgehog, Notch, and retinoic acid signaling pathways
In mammals, there are three Hedgehog (Hh) proteins: Sonic Hh,
Indian Hh, and Desert Hh [150]. The Hh ligands bind to patched 12-
span transporter-like receptors that inhibit the function of Smoothened
(Smo) serpentine receptors in the absence of ligands [151]. In zebrafish,
the Hh signaling promoted CM formation [152], whereas in mice, it has
been shown to be involved in the establishment of left and right
asymmetry, coronary vasculature, atrial septation and outflow tract
morphogenesis [153–155].
Notch signaling is associated with a wide range of developmental
processes and cell-fate decisions in various cell lineages [156]. In
mammals, there are four Notch receptors (Notch1–Notch4) and five
structurally similar Notch ligands (Delta-like 1 [DLL1], DLL3, DLL4,
Jagged1, and Jagged2) [157]. During embryonic cardiogenesis, the
Notch signaling controls right ventricle and outflow tract formation,
vascular smooth muscle development, chamber specification and tra-
beculation [158–161]. The SHF-specific deletion of Notch1 using the
Isl1-Cre mice promoted proliferation of Isl1+ progenitors and caused
overexpression of β-catenin in the SHF, indicating that the Notch sig-
naling interferes with the canonical Wnt signaling in the SHF and in-
hibits proliferation of the SHF progenitors, thereby promoting their
differentiation [151,162]. Intriguingly, it has been shown in zebrafish
embryos that differentiated atrial CMs could transdifferentiate into
ventricular CMs through activation of the Notch signaling [163].
Retinoic acid (RA), a biologically active metabolite of vitamin A
(retinol), is produced by retinaldehyde dehydrogenase 2 (Raldh2)
[164]. The RA signaling regulates the patterning of the SHF derivatives
along the anterior and posterior axes [165]. The developing hearts of
the Raldh2-KO murine embryos failed to undergo left-right (LR) looping
morphogenesis at E9.5 along with the abnormal expression of the
anterior SHF marker genes such as Tbx1 and Fgf8/10, and died at mid-
gestation (E10.5) [166,167]. Thus, the RA signaling is essential for
normal development of embryonic outflow tract and atria
[166,168,169]. Further, a recent study has revealed that RA signaling at
the mesoderm stage of development is required for atrial specification
and promotes differentiation into atrial-like CMs at the expense of
ventricular CMs in the in vitro hPSC cardiogenesis [170].
3.2. Genetic disorder of cardiogenic signaling pathways and transcription
factors in congenital heart disease
CHD is a serious issue of structural and functional deficits of the
developing heart and the most common malformation with high mor-
bidity in children, affecting 1/100 live births [171]. The most common
types of congenital heart defects are: ventricular septal defect (VSD),
atrial septal defect (ASD), tetralogy of Fallot (TOF), single ventricle
defects (SVD) (e.g., hypoplastic left heart syndrome [HLHS] and pul-
monary atresia [PA]), double outlet right ventricle (DORV), common
arterial trunk (CAT), pulmonary valve stenosis (PVS), patent ductus
arteriosus (PDA), transposition of the great arteries (TGA) and aortic
valve stenosis (AVS). Many factors that are classified into genetic and
environmental categories are associated with the etiology of CHD.
Normal cardiac development is depending on multiple signaling path-
ways spatiotemporally regulated, as noted above. If any of these
pathways are disrupted or incorrectly function, the specific cardiac
defects would be emerged as a form of syndromic or isolated CHD
(Table 1) [172]. Here we describe several important genes relating to
the cardiogenic signaling pathways, which have been identified as rare
causes of CHD. Further, various embryonic cardiac progenitor popula-
tions would also be most likely involved in the pathogenesis of CHD.
However, it is still an unaddressed question how the fundamental cel-
lular and/or molecular defects in cardiac progenitors lead to each of
specific morphologic phenotypes of CHD, which is currently under in-
vestigation [52,173].
3.2.1. Mutations in the TGF-β superfamily signaling pathway associated
with CHD
Disruption of individual genes in the TGF-β superfamily signaling
pathway often lead to embryonic lethality in mice [174]. Due to their
critical roles in cardiac development, mutations within the TGF-β su-
perfamily genes are also detected in human CHD [175,176]. Loeys-
Dietz syndrome (LDS) is one example of the TGF-β signaling malfunc-
tion-related CHD and an autosomal dominant genetic connective tissue
disorder [177]. The key feature of LDS is an enlarged aorta or an aortic
aneurysm, often detected in children. The aortic aneurysm may un-
dergo sudden dissection in the weakened layers of the aortic wall,
leading to greater risk for dying, and thereby, surgical repair of an-
eurysms is required for treatment [177]. These features of LDS are
overlapped with those of Marfan’s syndrome (MFS), which is caused by
mutations in the Fbn1 gene and an autosomal dominant genetic dis-
order of the connective tissue [178,179]. There are five types of LDS
which are distinguished by their genetic cause as follows: type I
(TGFβR1), type II (TGFβR2), type III (SMAD3), type IV (TGFβ2) and
type V (TGFβ3) (Table 1) [180–183]. The type I and II are the most
common forms of LDS. Mutations of these five genes encoding the TGF-
β signaling pathway-associated factors cause dysfunction of connective
tissue proteins (e.g., collagen), resulting in a wide variety of the phe-
notype of LDS, including arterial tortuosity, long limbs and fingers,
hypertelorism, split uvula, abnormal skin scars, aortic aneurysms, and
ASD [177,180].
Animal experiments, especially in mice, have been used to confirm
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human disease genes and to gain further insight into the cellular and
molecular mechanisms behind CHD. For example, TGFβ2-null mice
showed reduced muscularization of the outflow tract septum and in-
complete ventricular septation of the hearts [184]. Interestingly, using
theWnt1-Cre/TGFβR1 floxed mice, specific loss of TGFβR1 in the neural
crest led to 100 % penetrance of a persistent truncus arteriosus (PTA)
phenotype [185], or endothelial cell-specific loss of TGFβR1 using the
Tie2-Cre mice led to severely reduced cellularity of the atrioventricular
cardiac cushion [186]. These animal studies further shed light on the
essential role and molecular signatures of the TGF-β signaling pathway
on cardiogenesis.
Nodal signaling, which also belongs to the TGF-β superfamily, is a
critical component in establishing left-right asymmetry of the body-axis
and determining organ laterality in early embryogenesis [187]. Nodal,
Lefty2, ACVR2B and GDF1 are all associated with the laterality signaling
pathway [188–192], and mutations of these genes result in a variety of
cardiac laterality defects, including TGA, atrioventricular septal defects
(AVSD), DORV and TOF (Table 1).
3.2.2. Mutations in the Notch signaling pathway associated with CHD
Similarly to the TGF-β superfamily signaling pathways, disruption
of individual genes in the Notch signaling pathway often results in a
human genetic disease with cardiac phenotypes. Alagille syndrome is a
genetic multisystem disorder that can affect the heart, liver, kidneys,
eyes and other parts of the body. More than 90 % of patients with
Alagille Syndrome have cardiovascular anomalies, such as TOF, PVS,
AVSD and pulmonary arterial stenosis [193]. The majority (> 90 %) of
patients with Alagille Syndrome are caused by mutations in Jagged1
(Jag1), encoding a Notch signaling ligand, while a small number of
cases are caused by mutations in Notch2, encoding a Notch receptor
(Table 1) [194–197]. Homozygous Jag1-null (Jag1−/−) mice die from
hemorrhage possibly due to vascular defects during early embryogen-
esis [198], while heterozygous Jag1-/+ mice display eye defects but do
not exhibit other phenotypes such as cardiovascular anomalies [199].
In humans, however, Alagille Syndrome is caused by haploinsufficiency
of Jag1 [200].
Notch1 signaling is important at endothelial-to-mesenchymal
transformation, an early process in cardiac valve formation, which is
required in forming endocardial cushions from migratory mesenchyme
cells [201]. Mutations in Notch1 have been identified in patients with
isolated CHD, often presenting malfunctions of the aortic valve
(Table 1) [202,203].
3.2.3. Mutations in the retinoic acid signaling pathway associated with CHD
The RA signaling is essential for primitive heart tube formation.
Mutations in the Stra6 and Aldh1a2 genes associated with the RA sig-
naling have been linked to CHDs [204,205]. RA is synthesized from
vitamin A (retinol) that is transported to cells by retinol binding protein
via Stra6, a membrane protein involved in the metabolism of retinol. In
humans, mutations in the Stra6 gene are associated with Matthew
Table 1
Genes of the signaling pathways and transcription factors associated with CHD.
Gene Signaling pathway Cardiac phenotype Syndrome References
TGFβR1 TGF-β superfamily signaling pathway Aortic root aneurysm, Arterial tortuosity, ASD Loeys-Dietz [177]
TGFβR2 TGF-β superfamily signaling pathway Aortic root aneurysm, Arterial tortuosity, ASD Loeys-Dietz [177]
SMAD-3 TGF-β superfamily signaling pathway Aortic root aneurysm, Arterial tortuosity, ASD Loeys-Dietz [180,181]
TGFβ2 TGF-β superfamily signaling pathway Aortic root aneurysm, Arterial tortuosity, ASD Loeys-Dietz [180,182]
TGFβ3 TGF-β superfamily signaling pathway Aortic root aneurysm, Arterial tortuosity, ASD Loeys-Dietz [180,183]
ACVR1 TGF-β superfamily signaling pathway AVSD [172]
ACVR2B TGF-β superfamily signaling pathway TGA, DORV [187]
GDF1 TGF-β superfamily signaling pathway TGA, TOF, DORV [189]
LEFTY2 TGF-β superfamily signaling pathway AVSD, CoA, IAA [187]
NODAL TGF-β superfamily signaling pathway VSD, ASD, TOF [185,186]
SMAD6 TGF-β superfamily signaling pathway BAV [234]
TDGF1 TGF-β superfamily signaling pathway VSD, TOF [235]
JAG1 Notch signaling pathway TOF, PVS, AVSD, AVS Alagille [193,194]
NOTCH1 Notch signaling pathway AVS, BAV, CoA, TOF, VSD Adams-Oilver [199,200]
NOTCH2 Notch signaling pathway TOF Alagille [191,192]
ALDH1A2 Retinoic acid pathway TOF [201]
STRA6 Retinoic acid pathway VSD, ASD Matthew-Wood [202]
SOS1 RAS-MAPK pathway PVS, ASD, VSD Noonan [211]
SHOC2 RAS-MAPK pathway PVS, ASD, VSD Noonan [172]
PTPN11 RAS-MAPK pathway PVS, ASD, hypertrophic cardiomyopathy Noonan [210]
Leopard
Raf1 RAS-MAPK pathway TOF, hypertrophic cardiomyopathy Noonan [212,213]
Leopard
TAB2 IL-1 signal transduction pathway OFT defects [236]
VEGF Vascular Endothelial Growth Factor (VEGF) Signaling Pathway CoA, OFT defects [237]
FLT4 Vascular Endothelial Growth Factor (VEGF) Signaling Pathway TOF [238]
Gene Transcription Factors Cardiac phenotype Syndrome References
GATA4 GATA-binding TF ASD, PVS, TOF [226,227,228]
GATA6 GATA-binding TF OFT defects [239]
NKX2-5 Homeobox TF TOF, ASD, VSD, atrioventricular conduction defects [240]
NKX2-6 Homeobox TF TFO, DORV, VSD [240]
TBX1 T-box TF TOF, VSD, PTA, IAA DiGeorge [231]
TBX5 T-box TF ASD, VSD, conduction defects Holt–Oram [232]
TBX20 T-box TF ASD, TOF, aberrant valvulogenesis [233]
TFAP2B AP-2 TF PDA Char [241]
ZIC3 Zinc finger TF DORV, TGA, AVSD [242]
*This table includes representative genes associated with CHD, and the more comprehensive lists of them were excellently reviewed elsewhere [172,215].
ASD, Atrial septal defect; AVS, aortic valve stenosis; AVSD, Atrioventricular septal defect; BAV, bicuspid aortic valve; CoA, coarctation of aorta; DORV, double outlet
right ventricle; IAA, Interrupted aortic arch; PDA, patent ductus arteriosus; PTA, persistent truncus arteriosus; PVS, pulmonary valve stenosis; TOF, tetralogy of
Fallot; TF, transcription factor; TGA, transposition of the great arteries; VSD, ventricular septal defect.
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Wood Syndrome, which has a broad spectrum of malformations in-
cluding CHD such as ASD and VSD, anophthalmia, diaphragmatic
hernia, alveolar capillary dysplasia, lung hypoplasia and mental re-
tardation [205], although Stra6-null mice did not have overt cardiac
defects [206]. Aldh1a2 protein is an enzyme that catalyzes the synthesis
of RA from retinaldehyde and is responsible for production of almost all
RAs during early development [207]. In mice, deletion of Aldh1a2
caused heart defects with poor development of atria and sinus venosus
[166], while in zebrafish, deletion of Aldh1a2 caused emergence of the
enlarged heart with increased CM number [208]. Mutations in Aldh1a2
display TOF in humans (Table 1) [204].
3.2.4. Mutations in the Ras-MAPK signaling pathway associated with CHD
The Ras-mitogen activated protein kinase (MAPK) signaling
pathway activates cell proliferation, differentiation, maturation, sur-
vival and metabolism. Mutations in the genes related to this pathway
cause a wide range of multisystem anomalies, including CHD [209].
Noonan syndrome and related disorders are causally linked to germline
mutations in the Ras-MAPK signaling-associated genes [210]. Ap-
proximately 85 % of patients with Noonan syndrome have a variety of
cardiac defects, most commonly including PVS, ASD, and hypertrophic
cardiomyopathy [210]. Thus, Noonan syndrome is the second most
common genetic syndrome of CHD [211]. Ptpn11 is the first identified
causal gene of Noonan syndrome, accounting for 40–60 % of the cases
[210]. Subsequently, mutations in many of other genes were reported
to cause Noonan syndrome and Noonan-like phenotypes. Patients with
mutations in the Raf1 or Rit1 genes have hypertrophic cardiomyopathy
[212,213]. A minority of the cases with Raf1 mutations have TOF
[213]. Germline gain-of-function mutations in Sos1 can cause Noonan
syndrome, in which PVS is emerged more frequently in individuals with
Sos1 mutations (Table 1) [214].
3.2.5. Mutations in cardiac transcription factors associated with CHD
Cardiogenic signals, as noted above, are transmitted to multi-se-
quential transcriptional circuits that spatiotemporally regulate gene
expression during normal heart development. These transcriptional
networks rely on the functions of core transcription factors, many of
which can cause syndromic or isolated CHD when genetically mutated
(Table 1). Here we briefly describe only several important transcription
factors about their function and molecular signatures associated with
CHD, as they were reviewed more comprehensively elsewhere [215].
In humans, mutations in the homeodomain protein gene Nkx2-5
result in a plethora of CHDs, including ASD, VSD, TOF, DORV and atrio-
ventricular conduction defects [216,217]. Nkx2-5 is expressed in both
the FHF and SHF [218], and Nkx2-5-null mice exhibit embryonic
lethality due to faulty cardiac looping and insufficient myocardial dif-
ferentiation during chamber formation [219,220], along with lack of
the primordium of atrioventricular node [216]. It has also been re-
ported that Nkx2-5 interacts with other cardiogenic transcription fac-
tors Gata4 [221,222] or Tbx5 [223,224] within cardiac promoters,
cooperating in the transcriptional activation of cardiac target genes.
Recently, analysis of three missense single-nucleotide variants in the
Mkl2, Myh7, and Nkx2-5 genes in murine hearts and human induced
pluripotent stem cell (iPSC)-derived CMs confirmed the Nkx2-5 var-
iant’s contribution as a key genetic modifier [225]. Further, the triple-
heterozygous mice exhibited deep trabeculation in the left ventricular
walls that were similar to those seen in patients with left ventricular
non-compaction (LVNC) [225].
Gata4 is another important transcription factor during heart de-
velopment. In humans, mutations in the Gata4 gene can cause isolated
CHDs, including cardiac septal defects, PVS and TOF [226–228]. Gata4-
null mice exhibit embryonic lethality at E10.5 due to failure to establish
a primitive heart tube, while mice heterozygous for Gata4 mutations
develop CHD phenotypes, such as septation and endocardial cushion
defects [229].
The T-box transcription factors are also essential cardiac
transcription factors, which function in cardiac developmental pro-
cesses, such as the formations of outflow tract, heart chambers, and the
conduction system [230]. Haploinsufficiency of Tbx1 is the primary
cause of CHD in patients with DiGeorge syndrome whose cardiac phe-
notypes are commonly conotruncal malformations, including inter-
rupted aortic arch, persistent truncus arteriosus, TOF and VSD [231].
Mutations in Tbx5 cause Holt–Oram syndrome, which display upper
limb defects and heart defects, primarily septal and conduction defects
[232]. Patients that have mutations in Tbx20 have aberrant valvulo-
genesis, septal defects, TOF and cardiomyopathy [233]. Other CHD-
associated genes, e.g., transcription factor AP-2 beta (TFAP2B) and a
zinc finger transcription factor ZIC3, and their cardiac phenotypes
when mutated are shown in Table 1 [234–242].
3.3. Paracrine factors for cardiomyogenesis and vasculogenesis
Induction of myocardial repair via revascularization and/or pro-
liferation of CMs using growth factors (GFs) or other mediators has
aroused much interest within cardiovascular regenerative medicine.
Such GFs have the ability to quickly induce direct actions on a multi-
tude of cellular properties capable of enhancing reparative mechanisms
including cell growth, proliferation, migration, trans-differentiation
and others. The human body naturally expresses many GFs after injury,
but the expression is often too low and transient to induce tissue repair.
Therefore, the overexpression of certain GFs via gene or protein
therapies in pre-clinical and clinical studies is intensely being in-
vestigated as a treatment regime to treat ischemic cardiomyopathy and
prevent the progression of heart failure. Below we briefly highlight
some of the most essential GFs and other mediators as the paracrine
factors involved in mammalian vasculogenesis and cardiomyogenesis,
which are being applied in regenerative medicine (Table 2). For a more
comprehensive review of GF therapies in heart repair and regeneration
we refer the readers to the following reviews [243,244].
3.3.1. Vasculogenic growth factors
In the case of cardiac injury such as MI, therapeutic vasculo-/an-
giogenesis in myocardium is a promising mechanism for ischemic tissue
salvage. To date, some of the most encouraging angiogenic factors
capable of inducing regenerative mechanisms in the diseased setting
include, but are not limited to: vascular endothelial growth factor
(VEGF), FGF, stromal-derived factor-1alpha (SDF-1α), insulin-like
growth factor (IGF), hepatocyte growth factor (HGF), and TGF-β. The
exogenous administration of a vast majority of these angiogenic factors
have been shown to protect the myocardium at the onset of hypoxia/
ischemia injury and as such have been coined cardioprotective GFs. The
mechanisms and signaling pathways by which these factors act in order
to protect CMs are reviewed elsewhere [245–247]. Several of these GFs
have been explored clinically and we briefly summarize a few relevant
results below.
SDF-1 (CXCL12) and its receptor CXCR4 have been shown to play
key roles in cardiac development. Mutant rodent models with mis-
regulated CXCL12/CXCR4 give rise to VSD or truncated and irregular
coronary artery development [248,249]. SDF-1 is a chemotactic factor
that has been shown to recruit stem cells to sites of injury from the bone
marrow in order to help grow new blood vessels as well as prevent cell
death and reduce scar sizes when administered to the damaged heart
[250]. More recently SDF-1 has gained appeal for clinical use in pa-
tients with heart disease. The STOP-HF was a double blinded, placebo
controlled clinical study that tested the safety and efficacy of plasmid
SDF-1. In this study the administration of SDF-1 to ischemic heart pa-
tients reported increased left ventricular ejection fraction (LVEF)
compared with placebo groups at 12 months and the study concluded
no adverse effects were seen from SDF-1 treatment [251].
HGF and its receptor c-Met, a transmembrane tyrosine kinase, are
transiently expressed in CMs in early developmental stages of the ro-
dent heart [252]. HGF has been identified as a marker of acute MI and
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has gained value as a potential angiogenic factor [253,254]. In-
tracoronary administration of HGF and IGF (as described below) in pre-
clinical large animal models have been shown to activate endogenous
cardiac stem cells which foster the generation of new myocardium and
improved ventricular function [255].
VEGF is a major endothelial cell mitogen capable of driving an-
giogenesis and vasculogenesis [256]. VEGF and its receptors play es-
sential roles in many different aspects regarding the developmental
formation of the cardiovascular circuitry [257]. Early reparative studies
employing VEGF-A administration through plasmid and recombinant
protein delivery systems documented angiogenic stimulation and en-
hanced cardiac repair in large pre-clinical animal models of heart dis-
ease [258,259]. However, studies employing VEGF-A gene and protein
therapies in patients with coronary artery disease have been pre-
dominantly negative and did not demonstrate significant clinical ben-
efits [260–262]. In contrast to these studies, some Phase I/II clinical
cardiac studies have reported positive results from VEGF-A protein or
gene therapy [263–265]. On-going gene therapy trials and explanations
of discrepancies in these studies are described elsewhere [266]. More
recently VEGF-A has been administered to the diseased myocardium in
the form of a therapeutic mRNA agent with much success, as described
in detail below (see Section IV).
FGF-2 (basic FGF) and FGF-4 are also known as pro-angiogenic
factors [267]. They have pleiotropic roles in various cell types and act
as mitogenic, angiogenic and survival factors that are involved in cell
proliferation and differentiation [267,268]. FGF-4 likely plays a role in
more mature blood vessel formation and has been shown to have an
additive role in the induction of VEGF synthesis [269]. In a series of
AGENT clinical trials, it has been indicated that there was a significant
and gender (women)-specific beneficial effect of intracoronary adeno-
virus-containing FGF-4 treatment in patients with coronary artery dis-
ease and chronic stable angina [270,271].
3.3.2. Cardiomyogenic growth factors
In recent years, the concept of the adult heart being a terminally
differentiated organ has been challenged [62]. This work and others has
prompted another concept for restoring large lost cell masses often seen
with infarction injuries; namely by employing GFs to trigger CM cell
cycle entry to induce proliferation and expansion of new functioning
populations of CMs. To date several promising GFs and secreted pep-
tides have been shown to activate CM cell cycle entry, which include
IGF, neuregulin-1 (NRG-1), acidic FGF (FGF-1), and periostin (Postn).
IGF-1 is a small signaling peptide that shares 50 % homology with
insulin and regulates cellular growth and metabolism in the heart
[272,273]. IGF-1 signaling in cardiac muscles involves activation of
both MAP-kinase and phosphatidylinositol 3-kinase (PI 3-kinase)
pathways [274,275]. IGF-1 has been shown to prevent long-term left
ventricular remodeling in large animal models of cardiac injury through
mechanisms involving stem/progenitor cell activation, differentiation
and enhanced viability/survival [276]. Recent studies also showed that
epicardium secretes IGF-2, which activates IGF-1 receptors and subse-
quently ERK signaling in CMs to induce proliferation [277]. More re-
cently IGFs have been shown to play an emerging role in CPC pro-
liferation, expansion and induction into CMs, a valuable asset for PSC-
derived cell therapies, which are discussed in Section IV [278,279].
Interestingly, IGF proteins are heavily regulated by IGF binding pro-
teins (IGFBPs), which can positively regulate IGF stability by increasing
the biological half-life of the proteins in circulation; or negatively
regulate insulin signaling by blocking IGF receptors and/or insulin re-
ceptors [280,281]. There are six highly conserved IGFBP family mem-
bers expressed in vertebrates [282]. A number of the IGFBP family
members have been reported to display cardiomyogenic effects. For
example, a previous report affirmed a role for IGFBP-4 as a cardiogenic
GF where it enhanced CM differentiation in vitro and acted as a mole-
cular link between IGF and Wnt signaling [283]. More recently circu-
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diseases [284]. A more thorough understanding of the mechanisms of
actions driving and resulting from IGF-IGFBP interactions in the normal
heart as well as in the diseased cardiac settings are needed.
NRG-1 is a member of the epidermal growth factor (EGF) family of
membrane-tethered ligands and functions as a cardioactive GF released
from cardiac ECs, which has been shown to induce adult CMs to enter
the cell cycle, proliferate CMs, and improve cardiac function following
injury in rodent models via ErbB signaling [285,286]. More recently
and quite interestingly, the interplay between nerve growth factor-β
(NGF-β) and NRG-1 were reported to regulate CM proliferation and
thus enhance cardiac regeneration and repair in zebrafish and rodent
models [287]. Clinical studies that capitalize on patient puncture
biopsies in order to elucidate the effects of NRG-1 on human cardiac
tissue are underway (NCT02820233). Indeed, a completed Phase II
clinical study successfully confirmed a tolerable and safe dose of re-
combinant human NRG-1 (rhNRG-1) that was capable of enhancing
heart function and reverse-remodeling the left ventricle in patients with
chronic heart failure [288]. An additional clinical study is now aiming
to evaluate the functional efficacy in reducing death rates of heart
failure subjects receiving different doses of rhNRG-1 (NCT03388593).
FGF-1 is a multifunctional peptide involved in a multitude of dif-
ferent cellular functions that are mediated through interactions with
the four FGFRs [289]. In the heart, FGF-1 is secreted by a number of
different cell types including CMs, ECs, macrophages and fibroblasts
and plays a role in cardiac developmental-morphogenesis [290]. FGF-1
secretion intensifies under physiologically stressed conditions including
hypoxia or ischemic injury [291,292], and has been shown to reduce
apoptosis in CMs following vascular injuries in the heart [293]. The
underlying mechanisms regulating these pathways are not yet fully
understood. More recently the use of rhFGF-1 is being explored in re-
generative cardiovascular medicine. In preclinical studies of ischemia
reperfusion the delivery of FGF-1 (and NRG-1) using the NOGA
MYOSTAR™ injection catheter was met with improved cardiac function
and decreased transmural infarct sizes [294]. More recently the appli-
cation of rhFGF-1 is being considered in clinical studies for no-option
heart patients with coronary artery disease (NCT00117936).
Postn expression stems from, predominantly mesenchymal-related
cell types where it has been reported to play paramount roles in the
development and morphogenesis of cardiac valves [295,296]. Postn is a
non-structural extracellular membrane (ECM) protein, which has been
reported to be a major regulator of cell-matrix interaction, cell fate
determination, migration and proliferation in the developing heart
[297]. Using rat-derived mature CMs Kuhn et al. showed Postn treat-
ment significantly increased DNA synthesis in CMs in vitro [298]. This
team further explored the role of Postn to induce CM cycling in vivo,
where Postn stimulated and sustained CM cell-cycle activity thus im-
proving cardiac functional parameters and decreased scar sizes fol-
lowing myocardial injury. However, some conflicting studies report no
effect of Postn on CM cell-cycle entry [299] or confirmed the admin-
istration of Postn was capable of enhancing CM proliferation, but was
associated with negligible side effects of increased fibrosis in a large
animal model of heart disease [300]. Thus, further investigations are
required to confirm the authentic effects and mechanisms of Postn on
cardiomyogenesis.
3.3.3. Growth factor cocktails for cardiac repair
In order to stimulate effective repair to the damaged heart following
ischemic injury, medical research teams have begun to employ com-
binatorial cell survival and regenerative GFs to co-stimulate cardio-
myogenesis and vasculogenesis. In a large animal model of left-anterior
descending artery (LAD)-ligation, Tao et al. employed adeno-associated
viruses (AAVs) expressing VEGF and another angiogenic peptide,
namely angiopoietin-1 (Ang-1), which were co-administered to infarct
and peri-infarcted regions [301]. Co-expression of both factors were
met with higher vascular densities, increased CM proliferation and
activation of pro-survival pathways that decreased apoptosis in CMs
when compared to control animals. Another study employing a rat MI
model demonstrated the sequential delivery of two angiogenic factors,
one potent mediator of neo-angiogenesis and another that importantly
should help stabilize sprouting neovessels [302]. In this study, VEGF-A
and platelet-derived growth factor-BB (PDGF-BB) were sequentially
injected intramyocardially following injury through a fibrin gel system.
The beneficial effects of sequential delivery of VEGF-A and PDGF-BB
recombinant proteins were improved cardiac function, improved ven-
tricular wall thickness and reduced inflammatory/fibrotic responses, as
compared to controls. Thus, a GF cocktail strategy rather than a single
GF approach appears to hold promise for cardiomyogenesis and vas-
culogenesis to the damaged hearts, but successful treatment strategies
involving multiple GFs need to involve effective routes of administra-
tion. For example, in a study by Hwang et al. the team administered a
cocktail of four GFs as soluble factors: FGF-2, SDF-1, IGF-1 and HGF
that were delivered intraperitoneally in rats following cardiac injury –
the results of which had no effect on cardiac functional improvement,
reduction in scar sizes or improved microvasculature [303]. Controlling
the expression kinetics of a GF cocktail through dose, timing and
methods of administration could go someway to help mitigate the in-
jury induced by MI and add value to cardiovascular regenerative pro-
grams.
3.3.4. Alternative mediators of cardiomyogenesis
In recent years, investigational studies aiming to employ cell-cycle
phase activators/mediators as a potential source for regenerative repair
in the heart after injury have dramatically been increased. In mam-
malian CMs, cyclins and cyclin-dependent kinases (CDKs) help or-
chestrate cell-cycle state and transitions [304]. The mechanisms which
underlie the CM cell-cycle in development and regeneration are dis-
cussed in detail elsewhere [305]. In general, the expression of these
cell-cycle regulators to induce adult CM division has been met with
several caveats including nuclear division without proliferation/cyto-
kinesis or instability following cellular division [306–308]. Yet induc-
tion of the cell cycle continues to emerge as a possible intervention for
inducing heart repair. One previous study showed the transgenic ex-
pression of cyclin D2 improved survival rates in a mouse model of
transverse aortic constriction (TAC) [309]. The TAC-treated mice pre-
sented with hypertrophy, which was met a 50 % increase in CM
number. In another study cyclin D2 lentiviral-mediated gene transfer
increased cell proliferation in human iPSC (hiPSC)-derived CMs [310].
The same team went on to show beneficial effects in mice following MI
injury, where the cyclin D2 transfected hiPSC-derived CMs increased in
cell number between 1 and 4 weeks after implantation, which improved
cardiac function and reduced infarct size. Also of interest was a recent
study that extended proliferation of adult CMs through miR-128 dele-
tion [311]. The deletion had an effect on suppressing p27 (a cycling-
dependent kinase inhibitor) and subsequently activated cyclin E and
CDK2. Together the stimulation of cell cycle re-entry of adult CMs re-
duced fibrosis and cardiac dysfunction in response to MI. Of further
interest was a large animal study that revealed a regenerative response
by employing adenoviral delivery of cyclin A2 following catheter-based
MI [312]. Six weeks after treatment, MRI based assessment revealed
nearly a 20 % increase in cardiac contractile function and histological
evaluation determined a substantial increase in CM mitoses and de-
creased fibrosis. These data provide compelling evidence for continued
development of cell-cycle regulation for cardiac regenerative therapies.
In line with the studies from above, a more recent publication ele-
gantly identified pertinent cell-cycle mediators expressed during fetal
cardiomyogenesis and subsequently used adenovirus to over-express
them in rodent and human adult CMs, resulting in the induction of
adult CM cell division in vitro [313]. Interestingly, when the team ad-
ministered a discrete cocktail comprising of CDK1, CDK4, cyclin B and
cyclin D1 to an acute or sub-acute cardiac injury model, substantial and
effective in vivo CM proliferation was noted, up to 15–20 %, a response
that was ultimately capable of driving functional cardiac improvement.
N. Witman, et al. Seminars in Cell and Developmental Biology 100 (2020) 29–51
37
The Hippo signaling pathway controls the size of several organs
during development [314] and inhibits CM proliferation through in-
activating the transcriptional coactivator Yap, which is a terminal ef-
fector of the Hippo pathway [315,316]. Yap has robust CM mitogenic
activity linked to the PI3K-AKT pathway, as forced expression of con-
stitutively active Yap in CMs strongly stimulated their proliferation in
both neonatal and adult murine hearts [317,318]. Thus, the Hippo/Yap
pathway has become a therapeutic target for stimulating CM pro-
liferation and heart regeneration following MI injury. Indeed, a recent
study using AAVs to overexpress activated Yap in adult CMs has de-
monstrated that this treatment could improve myocardial function and
survival after MI in mice [319].
Heart pathologies after MI highlight extensive remodeling of the
extracellular matrix (ECM) resulting in formation of fibrotic scars and
reduced cardiac function. Although the role of the ECM during heart
regeneration was largely unknown, a recent elegant study has un-
covered a new mechanism of Yap inhibition by the dystrophin-glyco-
protein complex (DGC) and its component dystroglycan 1, which di-
rectly binds to Yap to block CM proliferation in neonatal mice [320].
Notably, Bassat et al. have identified the ECM protein Agrin that dis-
assembles the DGC through mediating Yap and ERK signaling path-
ways, and thereby induces the full regenerative capacity of neonatal
mouse hearts [321]. Importantly, the team has also shown that a single
administration of Agrin promotes heart regeneration in adult mice after
MI, highlighting fundamental roles of the ECM in cardiac repair.
Similarly to the Hippo pathway and the DGC-Yap interaction to
inhibit CM proliferation, cumulative evidence suggests that poly-
ploidization and/or binucleation of CMs, which occur naturally in the
post-natal mammalian heart, create a barrier to heart regeneration
[322,323]. Several recent studies have revealed that simply increasing
DNA content and/or promoting polyploidization in the highly re-
generative zebrafish CMs via knockdown of the cytokinesis inducer Ect2
or the Tnni3k interacting kinase, are sufficient to suppress their pro-
liferative potential during regeneration, respectively [324,325]. This
suggests that blocking the emergence of polyploidy and binucleated
CMs and in turn, increasing the number of diploid and mononucleated
CMs by manipulating the Ect2-mediated or other cytokinesis-associated
pathways (e.g., Tnni3k), could offer a new therapeutic target for heart
regeneration.
Other signaling networks capable of influencing cell-cycle stimula-
tion in adult CMs and currently being heavily explored include Jak/
Stat, Wnt/β-catenin, p38 and Notch, and these pathways are discussed
in detail in the above sections or in a recent review [304].
4. Novel strategies of therapeutics for heart regeneration
Patients suffering from a vast majority of cardiovascular diseases are
treated with medications that help to alleviate symptoms and decele-
rate disease progression, however such drugs fail to restore and/or re-
pair damaged, necrotic tissue. Ischemia-related cardiomyopathies fol-
lowing the events of MI, for example, often lead to chronic heart failure
with high morbidity in patients where the progressive loss of functional
CMs is replaced by a non-functional fibrotic scar tissue [326]. This re-
sults in architectural remodeling and eventually adds strain to the
muscle, limiting the pumping capacity of the heart.
To date, there are multiple different approaches to promote cardiac
regeneration in the damaged hearts in humans (Fig. 1; Table 3). These
therapeutic strategies that are classified into cell-based or cell-free
therapy have been or are currently being investigated for their au-
thentic efficacies and potentials for heart regeneration in the settings of
pre-clinical and early clinical trials, as extensively reviewed elsewhere
[1,9,327]. Here, we shortly discuss the latest discoveries and notions in
these attempts. Further, we would like to mention that there is a body
of knowledge spanning decades of work regarding how “lower verte-
brate” species including aquatic salamanders and teleost fish, but not
mammals, naturally regenerate their hearts following cardiac injuries.
Understanding the natural mechanisms of heart regeneration in those
species has attracted much interest for researchers over the decades. To
go into detail on such studies, however, would greatly outweight the
scope of this review. For an up-to-date overview on these model systems
including some descriptions of molecular and cellular networks driving
naturally occurring regeneration, we direct the reader to the following
informative reviews [328,329].
4.1. Cell-based therapies
Stem cell therapies are emerging as the potential "white knights" for
cardiac repair, showcasing considerable promise for the generation of
new cardiac muscle in situ and improving heart function. The devel-
opment of cell-based therapies for heart regeneration have emerged
from many exogenous sources that include somatic stem/progenitor
cells such as bone marrow-derived cells (BMCs), hematopoietic stem
cells (HSCs), MSCs, and adult cardiac progenitor cells (CPCs); or the
directed differentiation of hPSCs into CMs and/or CPCs (Fig. 1; Table 3)
[1,9,327]. Here, due to space limitations, we concisely focus on the
most recent advancements in novel cardiac cell therapies, namely those
involving transplantation of hPSC-derived cardiac cell types to repair
damaged myocardial tissue. Therapeutic potentials of adult CPCs are
discussed in Section 2, and for the recent and on-going clinical trials of
adult CPC therapies for heart regeneration, see [9]. Much controversy
and scientific misconducts surrounding the c-kit+ CPC research are
reviewed elsewhere [66]. We also refer readers to other excellent re-
views that describe other somatic stem cell therapies including BMCs,
HSCs and MSCs for heart regeneration [330–332]. Of interest, the re-
sults obtained from many of these reported clinical trials employing
adult somatic stem cells (BMCs, etc.) are quite contradictory and show
at best only modest therapeutic efficacy. These contradictory outcomes
may stem from a combination of methodological/technical processing
techniques used by different research teams, the parameters of the
study design, or even inherent limitations and/or various weak points
involved in the stem cell therapy itself, the details of which are dis-
cussed in recent reviews [333,334].
Another exciting strategy for heart regeneration is direct repro-
gramming of nonmyocytes such as fibroblasts to CM-like cells (induced
CMs), which is achieved by transduction of nonmyocytes with a cock-
tail of cardiac transcriptional regulators for myocardial transdiffer-
entiation [335,336]. This strategy is still in development, but results
have been promising, as described elsewhere (see review [337,338]).
4.1.1. Pluripotent stem cell-derived cardiomyocytes
Human ESCs are derived from the inner cell mass of the blastocysts.
They can indefinitely self-renew and are capable of differentiating into
all the major cell types of all 3 germ layers [339]. Human ESC-deri-
vatives have great therapeutic potential for treating cardiovascular
disease (CVD) yet continue to provoke ethical concerns [340]. In 2006
Takahashi and Yamanaka reported the remarkable story of generating
an iPSC from somatic cells using 4 defined transcription factors, the
characteristics of which were remarkably similar to ESCs [341]. Over
the years many protocols have been established which induce cardio-
myogenic differentiation from either human ESCs or iPSCs, namely
hPSCs [342–346]. Such technology holds much promise yet remain
hampered by several technical challenges, which often include the
production of immature CMs in a heterogenous population as well as
limitations in regards to generating these cells in large-scale quantities.
Regardless, numerous paramount studies have made significant strides
towards the realization of clinically translating hPSC-derived CMs for
cardiovascular diseases.
In an elegant study from the Murry lab, human ESC-derived CMs
(hES-CMs) were generated in clinical scale large batches and trans-
planted in diseased non-human primate (NHP) hearts following injury
[347]. Ischemia-reperfusion injury was met with extensive re-
muscularization (from the hES-CMs) in infarcted regions of the heart as
N. Witman, et al. Seminars in Cell and Developmental Biology 100 (2020) 29–51
38
early as 2 weeks post-transplantation. The engrafted human cells gave
rise to patchy muscle grafts that ranged in size, none-the-less the au-
thors revealed some evidence that supports electromechanical coupling
between the host and graft, however frequent arrhythmias were re-
ported which could be explained by either re-entry circuits or
spontaneous automaticity of the graft. Shortly following the study by
Chong et al., another team published some pioneering work employing
NHP-derived iPSC-CMs (iPS-CM) as a major histocompatibility complex
(MHC)-matched allogeneic transplantation model in NHPs [348]. In
this way, the team was able to reduce the risks of immune mediated
Fig. 1. Schema of potential therapeutic strategies for heart regeneration.
Novel therapeutic strategies for cardiac regeneration are classified broadly into cell-based (left) or cell-free therapies (right). The cell-based therapies involve
transplantation of human pluripotent stem cell (hPSC)-derived cardiac progenitor cells (CPCs), cardiomyocytes (CMs), or multiple cardiac cells (combination of some
among CMs, endothelial cells [ECs], smooth muscle cells [SMCs], cardiac fibroblasts [CFBs], etc.), or somatic stem/progenitor cells isolated and expanded from adult
organs and tissues. The cell-free therapies are conducted by administrating some cardiomyogenic and/or vasculogenic factor(s) in the forms of gene (plasmid or
mainly, viruses), modified mRNA (Mod-mRNA), or recombinant protein. Recently, small non-coding RNAs (i.e., microRNAs or antisense oligonucleotides [ASOs])
and extracellular vesicles (EVs) such as exomes have attracted much attention as novel non-cellular strategies for heart regeneration (also see Table 3). hESCs, human
embryonic stem cells; hiPSCs, human induced pluripotent stem cells.
Table 3
Chart of potential therapeutic strategies for heart regeneration.
Classification Methodology/category Cell or vector type Details/examples References
Cell-based therapies hPSC differentiation CPC SSEA1+ISL1+ [24,360]
HVP [359]
CM [347,348,349,350,351,352]





BMC/HSC CD34+, CD133+ see review [330,331,332]
MSC see review [330,331,332]
MSC/CPC Flk1+ [81]
Adult CPC c-kit+ see review [66]
CDCs [83,91,92]
Direct reprogramming Induced CPC [355,357]
Induced CM see review [337,338]
Cell-free therapies Gene (DNA) Plasmid VEGF, SDF-1 [250,251,258], also see review [391,392,393]
Adenovirus FGF4, VEGF, HGF, CDKs [270,271,313,384], also see review [391,392,393]
AAV SERCA2a, VEGF/Ang-1, YAP [301,319,386,387,388,389,390], also see review
[391,392,393]
LV Kit ligand [382,383]
RNA Mod-mRNA VEGF-A [396,398]
MicroRNA “Myo-miRs” miR1, miR21, miR199 [370], also see review [368,369,374]
ASO miR-25 [373], also see review [372,374]
Protein Recombinant
protein
HGF, IGF1, VEGF, NRG-1, FGF-1,
Periostin, PDGF, SDF-1, FGF-2
[255,263,265,288,294,298,300,302,303]
Exosome EV Derived from: ESCs, iPSCs, UC-
MSC, CDC, CM, PBMCs
see review [378]
AAV, adeno-associated virus; ASO, antisense oligonucleotide; BMC, bone marrow-derived cell; CDC: cardiosphere-derived cell; CDK, cyclin-dependent kinase; CM,
cardiomyocyte; CPC, cardiac progenitor cell; EC, endothelial cell; ESC, embryonic stem cell; EV, extracellular vesicle; HSC, hematopoietic stem cell; hPSC, human
pluripotent stem cell; HVP, human ventricular progenitor; iPSC, induced pluripotent stem cell; Mod-mRNA, modified mRNA; MSC, mesenchymal stem cell; LV,
lentivirus; PBMC, peripheral blood derived mononuclear cell; SMC, smooth muscle cell; UC-MSC, umbilical cord derived mesenchymal stem cell.
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graft rejection and demonstrated iPS-CMs endure long-term survival in
infarcted hearts. In addition, as shown by the Murry lab, histological
evaluation by Shiba et al. also demonstrated the iPS-CM transplantation
partially re-muscularized myocardium in patch-like islands. Further-
more, the transplantation significantly improved cardiac contractile
function, as shown by echocardiogram assessment in as little as 4 weeks
post-infarct and transplantation. The team was also able to demonstrate
electrical coupling between the host and graft, and this integration
likely explains the improved force generation, although several studies
describe similar functional improvements from paracrine-mediated ef-
fects [349,350].
Quite recently, several other studies investigated the physiological
basis for ventricular arrhythmias associated with hPSC-derived CM
engraftment in infarction models using NHP or porcine models, re-
spectively [351,352]. The first study concluded the basis for ventricular
arrhythmias associated with hPSC-derived CM grafting is likely to not
stem from reentry but arise from pulse generation from an ectopic ac-
tivation source. In the second report the study from the Laflamme team
point to focal automaticity driving ventricular tachycardia rather than a
reentrant phenomenon. Whether high rates of arrhythmia stem from re-
entrant pathways caused by electrical instability between graft and
host, increased sympathetic innervation, or impurities within the
transplanted grafts themselves, requires more attention. It has become
genuinely accepted that gap junction proteins like connexin-43 (Cx43)
are essential for electromechanical integration and serve to protect
against electrical instability [353,354]. Thus, engineering cells to in-
herently form gap junction proteins could perhaps increase electro-
mechanical coupling and help curb the occurrence of irregular ar-
rhythmias.
4.1.2. Cardiac progenitor cells
A major interest in innovative stem cell therapies has recently in-
volved employing the adult or hPSC-derived CPCs for cardiovascular
regenerative therapies [9]. In regards to regenerating infarcted heart
tissue, transplanted CPCs may have more favorable mechanisms than
immature CMs, as it is speculated the progenitor cells are more capable
of in situ proliferation, migration, and differentiation into multiple
lineages of cardiac cells as well as exert beneficial effects through the
release of robust paracrine factors. In fact, several reports have recently
demonstrated successful engraftment from administration of CPCs that
were induced with cell reprogramming from nonmyocytes and ex-
panded in vitro, resulting in decreased scar sizes in murine models of
heart disease [355–357]. Of further interest, one study directly com-
pared the differential regenerative effects between the hESC-derived
CM and CPC populations when administered in a nude rat MI model
[358]. The results revealed profound beneficial effects stemming from
both cell populations and the lack of any significant advantages of
employing one cell type over the other, however further studies should
be performed in order to address the ideal cell types, cell dose and
timing of administration to the damaged hearts.
Recent work from our lab demonstrated the potential for the hESC-
derived Isl1+ CPC population, termed as “human ventricular progeni-
tors (HVPs)” that are generated using a CM differentiation protocol
based on Wnt signaling modulation, to self-assemble into a functionally
mature ventricular muscle patch in vivo. Here the newly formed muscle
patch was capable of preserving myocardial function following MI in-
jury [359]. Most recently, the hESC-derived SSEA1+Isl1+ CPC has been
evaluated in the first clinical series of the human setting, where six
patients with ischemic cardiomyopathy and severe heart failure
(median age, 66.5 years; median LVEF, 26 %) received a median dose of
8.2 million of these CPCs [24,360]. After the 1-year follow-up, it was
shown that there was a modest decrease of LV volumes and an increase
in LVEF, which rose from 26 % (interquartile range [IQR]: 22–32 %) at
baseline to 38.5 % (IQR: 33.5–41 %) [360]. Notably, no evidence of
teratoma or adverse arrhythmia events was reported. Thus, this study
gives the rationale for setting the grounds for adequately powered
efficacy studies (Transplantation of Human Embryonic Stem Cell-de-
rived Progenitors in Severe Heart Failure [ESCORT] trial;
NCT02057900).
Several additional papers highlight novel approaches to cardiac
regeneration by employing novel cardiac stem/progenitor cell types.
For example, Oldershaw et al. derived a cardiac specific MSC-like cell
population from human patients that displayed multipotentiality by
giving rise to CMs and ECs in vitro [361]. In addition, these cells were
shown to be secretory and as such may offer cardioprotective and
beneficial effects when applied to myocardial injury models. In another
example, the Chaudhry lab has identified multipotent fetal-derived
Cdx2+ cells from placenta, which were capable of driving cardiac re-
pair in murine hearts following MI injury [362]. In brief, when ad-
ministered intravenously to infarcted mice, labeled fetal-derived Cdx2+
cells robustly homed to the dameged heart and differentiated to CMs
and blood vessels, resulting in significant improvement in contractility.
As such, these recent studies call attention to novel cellular therapeutic
advances and potential for cardiac cell therapy.
Despite these positive outcomes, some ethical and technical hurdles
are still impeding the clinical translation of the CPC-therapy for treating
CVD. For the clinical translation of CPCs to be fully realized, more
functional and safety studies are needed. Mechanistic feasibility studies
that explore cell dosage, surgical technologies involving the routes of
administration and surgical devices should be investigated in large
animal models, as the logistics and results are more easily extrapolated
to humans.
4.1.3. Combined cells therapy
More recently, the new concept that transplantation in combination
with multiple cardiac cell types, such as CMs, vascular ECs and SMCs,
and cardiac fibroblasts (CFBs), would have better outcomes for heart
regeneration following injury rather than injection of a single type of
cells (e.g., CMs alone) has attracted more interest in this field [363].
This is due to the fact that the myocardium is a complicated multi-
cellular organ and as such, multiple cell types are building up the entire
heart in a coordinated fashion. A logical corollary would be to enhance
the degree of therapeutic repair in the setting of the diseased heart;
complex multi-cellular populations capable of interaction and com-
munication with one another will be needed for regenerating the heart
to a fuller extent.
In line with this, a recent report highlighted the efficacy of a tri-
lineage cell transplantation incorporating human iPSC-CMs, ECs and
SMCs which significantly improved left-ventricular cardiac function
and decreased scar sizes following MI in a porcine model [364]. Of
significance, the hPSC-CMs were capable of integrating within the host
myocardium and the ECs and SMCs were further able to contribute to
the host vasculature. This study, and other similar studies which have
either combined ESC derivatives with MSCs in order to enhance pre-
servation of transplanted cell types [365]; or studies which are estab-
lishing conditions capable of wielding multiple cardiac cell types from
single differentiation protocols [366,367] are paving the way forward
towards advancing cardiac cell therapies.
4.2. Cell-free therapies
4.2.1. Noncoding RNAs, ASO, extracellular vesicles
The quest for discovery around novel bioactive drug therapies for
more effective and safer treatments for CVD has led to a multitude of
non-cellular strategies. Small non-coding RNAs such as microRNAs
(miRNAs) have been shown to fine-tune many biological processes in-
volved in heart development, disease and repair and are reviewed
elsewhere [368,369]. In a recent report by Gabisonia et al., the research
team assessed the effects of miR-199a in pig hearts after MI [370]. One
month following injury and treatment, the pigs treated with miR-199a
showed robust and significantly improved regional and global cardiac
function. The over-expression of miR-199a induced rapid and
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uncontrollable CM turnover through de-differentiation and prolifera-
tion, resulting in arrhythmic deaths to the pigs, despite increased
muscle mass and reduced fibrotic injury. This study provides novel
insights to expanding endogenous CMs following MI injury, however
the dosage of the therapy along with safe and efficacious routes of
administration are needed before bringing this miRNA therapy to light.
An alternative noncoding RNA, antisense oligonucleotides (ASOs),
are chemically active, short, single-stranded DNAs that contain com-
plimentary sequences to their RNA counterparts. ASO technology sup-
ports a variety of chemical modifications, all of which alter pharmo-
kinetic (PK) properties in a tissue specific manner [371]. ASO therapies
are emerging in a growing field of cardiovascular medicine, as their
precision could be used to restore cardiac function due to defective
hereditary conditions, several examples of which are discussed in a
recent review [372]. On the other hand, ASO technology could also be
employed to treat conditions of the chronic failing heart. For example, a
recent elegant study was able to employ antisense oligonucleotides
against miR-25, a suppressor of intra-cellular calcium handling during
heart failure, which unequivocally improved cardiac contractility
[373]. It is likely that ASO therapies will continue to advance techno-
logically for applications in wide-spread cardiovascular disease treat-
ments. Employing non-coding RNAs as therapeutic tools that target the
cardiovascular system show much promise, but many challenges ensue
which are discussed elsewhere [374]. Extracellular vesicles (EVs) such
as exosomes are one way these small noncoding particles traverse and
communicate through intercellular trafficking [375]. Exosomes have
been shown to transport RNAs, lipids and proteins even among cardiac
cells [376,377]. In fact, many biological sources of [378,379] exosomes
for myocardial repair have been reported and include stem cells, body
fluids and somatic cell types (see Table 3). Exosomes may mediate
cardiac repair after injury and the therapeutic role for exosomes in
cardiac repair are reviewed elsewhere [378].
4.2.2. Gene therapy
Although gene therapies were once touted to be a potential treat-
ment option for cardiovascular diseases, at the time of this review very
few results report clinical significance [266]. Vehicles used in cardio-
vascular gene therapy include non-viral (naked plasmid DNA) and viral
vectors. DNA plasmids are often met with low transfection efficiency
[380] and as such various kinds of viral vectors have gained momentum
for applications in gene therapy [381]. Adenoviruses (AVs), AAVs and
lentiviruses (LVs) all have the capability to deliver genetic material to
cardiac cell types and as such have become of great interest to re-
searchers. A previous study employed LVs to express Kit ligand (KL) in
mice undergoing MI [382]. Here the team showed injection of the LV-
KL at the time of MI later attenuated ventricular remodeling and im-
proved post-MI survival rates. It was speculated that the over-expres-
sion of the KL may have enhanced bone marrow cells homing to the
infarcted heart where they play a role in repair through paracrine/au-
tocrine effects and/or transdifferentiation and engraftment. Of note,
LVs act by stably integrating into the host genome of target cells making
them a harbinger for insertional mutagenesis and thus have not been
used in the clinical trials for patients with heart failure. It is speculated
that in understanding site selections and mechanisms driving interac-
tions with chromatin, LVs may become accepted for gene therapy
[383].
AVs are non-integrating and have been shown to achieve high levels
of transduction in CMs, the success of which, however, may require
direct IM injection [384]. AV therapies carry the weight of being
worldly known for the death of a young man who developed a systemic
inflammatory response to AV [385], which lead to organ-wide failure.
As such enthusiasm for exploring AVs in gene therapy studies have
become grandly lost.
AAVs seem to be the current vector of choice in a number of car-
diovascular gene therapy clinical trials [386]. Multiple strains of AAVs
have been identified, where AAV1, AAV6, AAV8 and AAV9 are
genuinely accepted as the most cardiotropic serotypes (that is, they
have a specificity for infecting CMs in particular) [387,388]. Gene
therapies employing AAVs could potentially replace deficient proteins
in order to protect against the progression of dilated cardiomyopathy in
patients with heart failure. A recent Phase1/2 clinical trial delivered
AAV1/SERCA2a, which is a gene that regulates CM contraction and
relaxation by transporting Ca2+ from the cytosol into the sarcoplasmic
reticulum during diastole, via intracoronary infusion in patients with
advanced heart failure, the results of which showed limited safety
concerns and marginal cardiac improvements [389]. However, the re-
sults in the larger Phase 2b trial involving 250 patients with moderate-
to-severe heart failure revealed that at the 1-year follow-up, the mor-
tality rate was similar between the placebo and AAV1/SERCA2a-treated
groups and the time to recurrent events such as hospitalization was not
significantly improved in AAV1/SERCA2a group [390].
Regardless, continued improvements in gene delivery methods and
control of transgene expression are heavily required if gene therapy
trials are to be successful. Discussions concerning updated concepts that
include novel vector design and various gene delivery methods are
discussed in detail elsewhere [391]. Further technological shortcomings
including patients' immunological responses to these treatments, which
are causing clinical conflicts or failures, are reviewed elsewhere
[392,393]. In addition, we briefly introduced several cases of recent
promising gene therapy, as well as recombinant protein therapy, in the
field of cardiac regenerative medicine in Sections 3 and 4.
4.2.3. Synthetic chemically modified mRNAs
Messenger RNAs (mRNAs) containing synthetic modified nucleo-
sides (modRNA) have become a technology gaining wide recognition in
novel therapeutic platforms including genetics, immunotherapy and
cancer [394,395]. More recently, the full in vivo therapeutic potential of
modRNA technology has been realized in the cardiovascular field.
Following cardiac injury, direct intramyocardial injections of modRNA
encoding the VEGF-A gene was shown to enhance neoangiogenesis
leading to improved cardiac function in small and large animals where
administered in lipid nanoparticles (LNPs) or a biocompatible citrate
formulation [101,396,397]. Notably, due to its adequate pharmacoki-
netics and/or other reasons, there have been no adverse effects in the
VEGF-A modRNA therapy, such as aberrant vascular growth, weak
neovessel formation with considerable extravasation, and cardiac
edema, which were often reported in the previous preclinical and
clinical studies testing the efficacies and safety of the VEGF-A re-
combinant protein or gene therapy for cardiovascular disease
[244,392,393].
On the basis of this evidence together with the ease of production
and expected safety profiles associated with modified mRNA tech-
nology, a Phase I first time in human (FTIH) study has already been
reported [398]. This study successfully demonstrated the safety toler-
ability and efficacy of dermal administrations of modRNA encoding the
VEGF-A gene in diabetic patients. Thus, it is expected that modRNA
technologies will continue to gain widespread attention and the spec-
trum of clinical conditions that could benefit from this technology will
expand further.
4.2.4. Other synthetic particles
In line with the production of synthetic chemical modRNA for car-
diac therapies, alternative novel bioengineered synthetic particles have
begun to gain momentum as novel treatment regimes for cardiac in-
dications. For example, a recent paper by Vandergriff et al. elegantly
employed a synthetic targeting peptide which was capable of inducing
the homing of intravenously infused exosomes into infarcted rodent
hearts [399]. By targeting exosomes to the heart with a synthetic
construct, the rodents had reduced fibrotic injuries and scar sizes along
with improved cardiac function and improved angiogenesis following
myocardial injury. In another study, Tang et al. employed cell-mi-
micking microparticles (CMMP), which exerted reparative effects
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similar to those effects seen by paracrine secreting adult stem/cardiac
cells [400]. Interestingly, in a mouse model of MI, these CMMPs exerted
cardioprotective outcomes and promoted myocardial repair, while
failing to stimulate T-cell infiltration indicating their safety tolerability.
Further testing in large animal models highlighting efficacy and clinical
delivery routes need to be addressed. However, the combination of
synthetic bio-engineered technology platforms holds promise in the
future of regenerative medicine.
4.3. Future perspectives
Recent discoveries and advanced knowledge of the cardiac pro-
genitors and the cardiogenic paracrine mediators hold great promise for
heart regeneration through stimulating CM proliferation and blood
vessel growth in the damaged hearts. Yet multiple issues, including
inefficient induction of CM proliferation even by using novel ap-
proaches, increased cancer risk in noncardiomyocytes due to activating
cell cycle, teratoma risk by transplanted immature stem cells, and in-
complete electrical coupling between transplanted cells and host car-
diac tissue need to be fully addressed before clinically applying these
cell-based or cell-free strategies for heart disease. In regard to the
cancer risk, for example, both NRG-1 and Yap signals have oncogenic
potentials and are involved in some types of cancers [401,402], re-
quiring precise targeting of mitogenic stimuli to CMs in order to
minimize oncogenic risk. One of the keys to success for heart re-
generation is to recapitulate the developmental paradigm of paracrine
mediator cues acting on the specific cardiac progenitors to build the
heart, routinely observed in embryogenesis. In this regard, a combi-
natorial approach that brings together cell-based and cell-free therapies
will attract much interest in future and promising regenerative medi-
cine for heart disease. For example, we envision the combined admin-
istration of VEGF-A modRNA and HVPs in the damaged hearts as an
interesting direction to stimulate both vasculogenesis and cardiomyo-
genesis. Collectively, all of the ongoing efforts by cardiac/stem cell
biologists and clinical cardiologists will someday open the door and
novel paths to groundbreaking advances in the establishment of heart
regeneration and thereby in the treatment of congenital and acquired
heart diseases in children and adults.
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